RIA
VRTX icon

Realta Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Realta Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,079
Closed -$523K – 416
2024
Q3 		$523K Buy
+1,079
New +$518K 0.24% 103
2024
Q2 		– Sell
-785
Closed -$328K – 829
2024
Q1 		$328K Buy
+785
New +$332K 0.07% 304
2021
Q1 		– Sell
-1,459
Closed -$345K – 392
2020
Q4 		$345K Buy
+1,459
New +$335K 0.1% 228
2020
Q3 		– Sell
-1,146
Closed -$333K – 372
2020
Q2 		$333K Sell
1,146
-110
-9% -$29.8K 0.11% 231
2020
Q1 		$299K Sell
1,256
-412
-25% -$94.5K 0.13% 207
2019
Q4 		$371K Sell
1,668
-39
-2% -$7.89K 0.1% 232
2019
Q3 		$290K Buy
1,707
+85
+5% +$15K 0.08% 263
2019
Q2 		$299K Buy
1,622
+572
+54% +$100K 0.08% 258
2019
Q1 		$194K Buy
+1,050
New +$194K 0.09% 268

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Realta Investment Advisors's VRTX Position: Q4 2024 in Review

Realta Investment Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 1,079 shares — an estimated $523K sold.

Realta Investment Advisors first reported a position in VRTX in Q1 2019 and held it in 9 quarters. The position peaked at $523K in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Realta Investment Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Realta Investment Advisors sold 1,079 Vertex Pharmaceuticals shares in Q4 2024, an estimated $523K.
  • Realta Investment Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Realta Investment Advisors's Vertex Pharmaceuticals position peaked at $523K in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Realta Investment Advisors's 13F filing for Q4 2024, filed 28 Jan 2025.